Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) shares were up 5.9% during mid-day trading on Friday following insider buying activity. The stock traded as high as $4.92 and last traded at $4.83, approximately 2,010,802 shares changed hands during trading. A decline of 1% from the average daily volume of 2,032,246 shares. The stock had previously closed at $4.56.
Specifically, Director Charles B. O’keeffe bought 10,000 shares of the stock in a transaction on Friday, October 11th. The shares were purchased at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the director now directly owns 553,376 shares of the company’s stock, valued at approximately $2,600,867.20. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.70% of the company’s stock.
A number of research analysts have commented on CPRX shares. Piper Jaffray Companies set a $8.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. SunTrust Banks reiterated a “buy” rating and set a $11.00 price target (up previously from $9.00) on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 8th. ValuEngine downgraded Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. BidaskClub upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Finally, Cantor Fitzgerald upped their price target on Catalyst Pharmaceuticals from $10.00 to $12.00 in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.63.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. The company had revenue of $28.84 million for the quarter, compared to the consensus estimate of $17.99 million. The business’s revenue was up 2883900.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.06) EPS. On average, sell-side analysts forecast that Catalyst Pharmaceuticals Inc will post 0.34 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in shares of Catalyst Pharmaceuticals by 2.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 956,946 shares of the biopharmaceutical company’s stock worth $3,569,000 after purchasing an additional 18,470 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $101,000. First Allied Advisory Services Inc. lifted its position in shares of Catalyst Pharmaceuticals by 7.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 29,000 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 2,000 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $293,000. Finally, Paradigm Capital Management Inc. NY acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $77,000. 59.77% of the stock is owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: Futures Contract
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.